Marc-Olivier Fischer

Marc-Olivier Fischer

Auto-generated profile, based on publicly available information

Marc-Olivier Fischer

Institut Aquitain du Cœur, Clinique Saint-Augustin, Elsan, Bordeaux Cedex, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2021 in Critical Care
Verified
Journal Article
Open access
PDF file
RDRichard Descamps
Richard Descamps
Moussa, Mouhamed D.Moussa, Mouhamed D.
Moussa, Mouhamed D.
EBemmanuel besnier
emmanuel besnier
MFMarc-Olivier Fischer
Marc-Olivier Fischer
SPSebastien Preau
Sebastien Preau
DCDamien Du Cheyron
Damien Du Cheyron
Background: Hemorrhagic events remain a major concern in patients under extracorporeal membrane oxygenation (ECMO) support. We tested the association between anticoagulation levels and hemorrhagic events under ECMO using anti-Xa activity monitoring. Methods: We performed a retrospective multicenter cohort study in three ECMO centers. All adult patients treated with veno-venous (VV)- or veno-arterial (VA)-ECMO in 6 intensive care units between September 2017 and August 2019 were included. Anti-Xa activities were collected until a hemorrhagic event in the bleeding group and for the duration of ECMO in the non-bleeding group. All dosages were averaged to obtain means of anti-Xa activity for each patient, and patients were compared according to the occurrence or not of bleeding. Results: Among 367 patients assessed for eligibility, 121 were included. Thirty-five (29%) presented a hemorrhagic complication. In univariate analysis, anti-Xa activities were significantly higher in the bleeding group than in the non-bleeding group, both for the mean anti-Xa activity (0.38 [0.29–0.67] vs 0.33 [0.22–0.42] IU/mL; p = 0.01) and the maximal anti-Xa activity (0.83 [0.47–1.46] vs 0.66 [0.36–0.91] IU/mL; p = 0.05). In the Cox proportional hazard model, mean anti-Xa activity was associated with bleeding (p = 0.0001). By Kaplan–Meier analysis with the cutoff value at 0.46 IU/mL obtained by ROC curve analysis, the probability of survival under ECMO without bleeding was significantly lower when mean anti-Xa was > 0.46 IU/mL (p = 0.0006). Conclusion: In critically ill patients under ECMO, mean anti-Xa activity was an independent risk factor for hemorrhagic complications. Anticoagulation targets could be revised downward in both VV- and VA-ECMO.

14 August 2025 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
MFMarc-Olivier Fischer
Marc-Olivier Fischer

27 November 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
FSFlorimond Suard
Florimond Suard
MMMartin Mombrun
Martin Mombrun
MFMarc‐Olivier Fischer
Marc‐Olivier Fischer
JHJean‐Luc Hanouz
Jean‐Luc Hanouz
JDJean‐Baptiste Decros
Jean‐Baptiste Decros
RDRichard Descamps
Richard Descamps

22 April 2026 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
MFMarc-Olivier Fischer
Marc-Olivier Fischer